Literature DB >> 15787787

Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients.

Jung Sue Kim1, Diego H Aviles, Douglas M Silverstein, Pamela L Leblanc, V Matti Vehaskari.   

Abstract

Tacrolimus has become an effective alternative to cyclosporine as a component of primary immunosuppression in pediatric renal transplant patients, but the information on the pharmacokinetic characteristics of tacrolimus in young patients is still limited. The primary objective of this study was to determine the effect of patient age, ethnicity, and concurrent steroid administration on tacrolimus pharmacokinetics in pediatric renal transplant patients. The study population consisted of 30 pediatric patients, age 1.5-18.6 yr, who received a kidney transplant between July 1999 and February 2004. After twice daily dosing was stabilized based on clinical judgment, at least 5 days postoperatively, tacrolimus levels were drawn prior to, and 1, 2, 4, 8, and 12 h after the morning dose. The mean dose of tacrolimus was 0.12 mg/kg/dose. Mean trough level was 11.9 +/- 5.0 ng/mL. Mean area under the curve (AUC) was 192 +/- 84 with a range of 78-360 h x (ng/mL). The correlation between trough level and AUC was only fair (r = 0.74); later time points correlated better with AUC, and an excellent correlation (r = 0.96) was obtained between the mean of trough and 2-h level (C(2)) and AUC. There was a negative correlation between age and dose per body weight (r = -0.68). African-American patients had marginally lower drug exposure with similar dosing. Three age groups (<5, 5-12, and >12 yr) were compared with respect to dosing and AUC. Despite similar AUC in all three groups, the mean dose per kg required to achieve the AUC was 2.7- and 1.9-fold higher in the <5 and 5-12-yr groups, respectively, compared with the >12-yr group. Nine of the 30 patients were on a totally steroid-free regimen. Their tacrolimus dose and trough levels were similar to those of steroid-exposed patients, but their mean AUC was 41% higher. Our results show an inverse correlation between age and required tacrolimus dose, wide interindividual variation, and greater exposure with steroid-free regimen despite no change in trough level.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15787787     DOI: 10.1111/j.1399-3046.2005.00263.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  25 in total

1.  Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients.

Authors:  Violette Gijsen; Seema Mital; Ron H van Schaik; Offie P Soldin; Steven J Soldin; Ilse P van der Heiden; Irena Nulman; Gideon Koren; Saskia N de Wildt
Journal:  J Heart Lung Transplant       Date:  2011-09-17       Impact factor: 10.247

2.  A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.

Authors:  Sherwin K B Sy; Jules Heuberger; Sireen Shilbayeh; Daniela J Conrado; Hartmut Derendorf
Journal:  AAPS J       Date:  2013-08-30       Impact factor: 4.009

3.  Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation.

Authors:  Pier Luigi Calvo; Loredana Serpe; Andrea Brunati; Antonello Nonnato; Daniela Bongioanni; Dominic Dell' Olio; Michele Pinon; Carlo Ferretti; Francesco Tandoi; Giulia Carbonaro; Mauro Salizzoni; Antonio Amoroso; Renato Romagnoli; Roberto Canaparo
Journal:  Br J Clin Pharmacol       Date:  2017-01-31       Impact factor: 4.335

4.  Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients.

Authors:  Tania Claeys; Maria Van Dyck; Rita Van Damme-Lombaerts
Journal:  Pediatr Nephrol       Date:  2009-11-03       Impact factor: 3.714

Review 5.  Therapeutic drug monitoring in pediatric renal transplantation.

Authors:  Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2014-04-25       Impact factor: 3.714

6.  Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium.

Authors:  Pamala A Jacobson; William S Oetting; Ann M Brearley; Robert Leduc; Weihau Guan; David Schladt; Arthur J Matas; Vishal Lamba; Bruce A Julian; Rosalyn B Mannon; Ajay Israni
Journal:  Transplantation       Date:  2011-02-15       Impact factor: 4.939

7.  Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients.

Authors:  Wei Zhao; May Fakhoury; Véronique Baudouin; Thomas Storme; Anne Maisin; Georges Deschênes; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2012-06-17       Impact factor: 2.953

8.  Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients.

Authors:  Diego Alberto C Cusinato; Riccardo Lacchini; Elen A Romao; Miguel Moysés-Neto; Eduardo B Coelho
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

9.  The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.

Authors:  Agnieszka A Prytuła; Karlien Cransberg; Antonia H M Bouts; Ron H N van Schaik; Huib de Jong; Saskia N de Wildt; Ron A A Mathôt
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

Review 10.  Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.

Authors:  J Michael Tredger; Nigel W Brown; Anil Dhawan
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.